Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2059 (LINC02059) is a non-protein coding RNA molecule classified as a long non-coding RNA (lncRNA); these RNAs are greater than 200 nucleotides in length and do not encode proteins[1][3][5]. LINC02059 is annotated in gene databases such as NCBI Gene (Gene ID: 100505878) and Ensembl (ENSG00000250544)[1][5]. While comprehensive functional characterization of LINC02059 is lacking, high-throughput studies have identified certain lncRNAs, including LINC02059, as being differentially expressed in cancer versus normal tissue, suggesting potential use as a biomarker for cancer, particularly lung cancer, where lncRNA expression patterns can aid in distinguishing tumors from normal samples[2]. There is currently no evidence that LINC02059 functions as a receptor, enzyme, transporter, or other direct therapeutic target. No drugs are known to act through LINC02059, and its specific molecular mechanisms or safety implications as a therapeutic target have not been established[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2059 (LINC02059).